Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?
Executive Summary
Takeda's Phase III win over Pfizer's Xalkori leaves oncologists cheering, but hankering for a head-to-head study against Alecensa, which is becoming the standard of care in the US for first-line ALK+ NSCLC.
You may also be interested in...
Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.